Symbols

RCUS

Arcus Biosciences·NYSE

--(--)

RCUS fundamentals

RCUS Q4 2025 Earnings

Arcus Biosciences (RCUS) released its earnings on Feb 25, 2026: revenue was 33.00M (YoY -8.33%), missed estimates; EPS was -0.89 (YoY +13.59%), beat estimates.

Revenue / YoY

33.00M

-8.33%

EPS / YoY

-0.89

+13.59%

Report date

Feb 25, 2026

RCUS Earnings Call Summary for Q4,2025

Casdatifan leadership: Phase III PEAK-1 enrollment on track; frontline TKI-free regimen shows 9% primary progression rate.
Market potential: $5B peak sales for casdatifan in RCC; 2026 ASCO GU data validates HIF-2 alpha class.
Financial strength: $1.0B cash runway to H2 2028; 2026 revenue guidance $45-55M.
Pipeline momentum: Immunology programs entering clinic; HCC expansion under evaluation.

Earnings

EPS

Revenue

Revenue & Expenses

RCUS has released its 2025 Q4 earnings report, with revenue of 33.00M, reflecting a YoY change of 26.92%, and net profit of -106.00M, showing a YoY change of -12.77%. The Sankey diagram below clearly presents RCUS's revenue sources and cost distribution.

Key Indicators

Arcus Biosciences (RCUS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Arcus Biosciences (RCUS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Arcus Biosciences (RCUS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Arcus Biosciences (RCUS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown